![Michael Berendt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Berendt
Président chez
Anchor Therapeutics, Inc.
Profil
Michael J.
Berendt is currently the Executive Chairman at Anchor Therapeutics, Inc. He previously served as the President & Chief Executive Officer at Aegera Therapeutics, Inc. and as the Group Director-Drug Discovery at Pfizer Inc. He has also served as an Independent Director at Waters Corp.
and as a Director at Onyx Pharmaceuticals, Inc. and Myriad Genetics, Inc. Additionally, he was the Managing Director at AEA Investors LP and RCT BioVentures.
He served as the Director, Chief Executive & Scientific Officer at Telesta Therapeutics, Inc. and as a Director at Northstar Neuroscience, Inc., Catalyst Bioscience, Inc., Trillium Therapeutics, Inc., Alethia Biotherapeutics, Inc., Research Corporation Technologies, Inc., Neomed Institute, and ProMetic Plasma Resources, Inc. He holds a doctorate degree from Drexel University, a graduate degree from Miami University, and an undergraduate degree from Ohio Dominican University.
Postes actifs de Michael Berendt
| Sociétés | Poste | Début |
|---|---|---|
Anchor Therapeutics, Inc.
 Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Designs and develops peptide modulators of G protein-coupled receptors | Président | - |
Anciens postes connus de Michael Berendt
| Sociétés | Poste | Fin |
|---|---|---|
| WATERS CORPORATION | Directeur/Membre du Conseil | 05/10/2021 |
| TELESTA THERAPEUTICS INC | Directeur Général | 01/11/2016 |
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Provides research and development of pharmaceuticals | Directeur/Membre du Conseil | 06/06/2014 |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and develops drugs | Directeur Général | 01/07/2011 |
RCT BioVentures
 RCT BioVentures Investment ManagersFinance RCT BioVentures invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology, medical devices & technology sectors. It provides financing for early stage capital requirements. | Corporate Officer/Principal | 01/12/2005 |
Formation de Michael Berendt
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
81
Relations au 1er degré
20
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 20 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Waters Corp.
 Waters Corp. Medical SpecialtiesHealth Technology Designs, manufactures, sells and services analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis | Health Technology |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Myriad Genetics, Inc.
 Myriad Genetics, Inc. Medical SpecialtiesHealth Technology Develops therapeutic and predictive medicine products | Health Technology |
Bayer Corp.
 Bayer Corp. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical, healthcare & agricultural products | Health Technology |
AEA Investors LP
 AEA Investors LP Investment ManagersFinance AEA Investors invests in middle-market companies located across the globe primarily in North America and Europe with an enterprise value of USD 400 million - 2.5 billion and an EBITDA of USD 5 - 200 million. The firm focuses on companies operating in the fields of industrial & industrial services, tech-enabled business services and tech-enabled healthcare services. It participates in buyout, growth, and debt transactions with an investment size of USD 50 – 250 million. The firm makes co-investments and acquires majority and minority interest. | Finance |
Telesta Therapeutics, Inc.
 Telesta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Researches and develops pharmaceutical products for the human and veterinary markets | Health Technology |
Northstar Neuroscience, Inc.
 Northstar Neuroscience, Inc. Medical SpecialtiesHealth Technology Provides solutions for stroke and other neurological diseases and disorders | Health Technology |
Catalyst Bioscience, Inc. /Old/
 Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Develops and markets catalytic biopharmaceutical products | Health Technology |
Anchor Therapeutics, Inc.
Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Designs and develops peptide modulators of G protein-coupled receptors | Health Technology |
RCT BioVentures
RCT BioVentures Investment ManagersFinance RCT BioVentures invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology, medical devices & technology sectors. It provides financing for early stage capital requirements. | Finance |
Drexel University
 Drexel University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Miami University
 Miami University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ohio Dominican University
 Ohio Dominican University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and develops drugs | Health Technology |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Provides research and development of pharmaceuticals | Commercial Services |
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets | Health Technology |
Research Corporation Technologies, Inc.
 Research Corporation Technologies, Inc. Financial ConglomeratesFinance Provides investment related services | Finance |
Neomed Institute
 Neomed Institute Pharmaceuticals: OtherHealth Technology Operates as a non-profit organization for pharmaceutical companies | Health Technology |
ProMetic Plasma Resources, Inc.
 ProMetic Plasma Resources, Inc. Medical/Nursing ServicesHealth Services Operates plasma donation centers | Health Services |
